KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Cash from Financing Activities (2017 - 2025)

Bionano Genomics' Cash from Financing Activities history spans 7 years, with the latest figure at $10.1 million for Q3 2025.

  • For Q3 2025, Cash from Financing Activities rose 67.35% year-over-year to $10.1 million; the TTM value through Sep 2025 reached $26.3 million, down 48.29%, while the annual FY2024 figure was -$13.7 million, 112.02% down from the prior year.
  • Cash from Financing Activities for Q3 2025 was $10.1 million at Bionano Genomics, up from $1.5 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $337.5 million in Q1 2021 and bottomed at -$21.6 million in Q1 2024.
  • The 5-year median for Cash from Financing Activities is $6.0 million (2024), against an average of $25.4 million.
  • The largest annual shift saw Cash from Financing Activities surged 212214.29% in 2023 before it tumbled 245.46% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at $2.0 million in 2021, then tumbled by 92.58% to $146000.0 in 2022, then surged by 46806.85% to $68.5 million in 2023, then plummeted by 94.32% to $3.9 million in 2024, then skyrocketed by 159.02% to $10.1 million in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Cash from Financing Activities are $10.1 million (Q3 2025), $1.5 million (Q2 2025), and $10.9 million (Q1 2025).